Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial-Reference-Cited by-同舟云学术

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial

Published:2018-01-09 Issue:6 Volume:18 Page:1424-1434
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

,Haynes Richard¹²,Blackwell Lisa¹²,Staplin Natalie²,Herrington William G.²,Emberson Jonathan¹²,Judge Parminder K.¹²,Storey Benjamin C.¹²,Landray Martin J.¹²,Harden Paul N.³,Baigent Colin¹²,Friend Peter⁴

Affiliation:

1. MRC Population Health Research Unit Nuffield Department of Population Health University of Oxford Oxford UK

2. Clinical Trial Service Unit Nuffield Department of Population Health University of Oxford Oxford UK

3. Oxford University Hospitals NHS Foundation Trust Oxford UK

4. Nuffield Department of Surgical Sciences University of Oxford Oxford UK

Funder

Novartis Pharmaceuticals UK Limited

NHS Blood and Transplant

Pfizer UK

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.14619

Reference39 articles.

1. Long-Term Renal Allograft Survival: Have we Made Significant Progress or is it Time to Rethink our Analytic and Therapeutic Strategies?

2. The Natural History of Chronic Allograft Nephropathy

3. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology

4. Calcineurin Inhibitor Sparing in Renal Transplantation

5. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Islet transplantation in kidney transplant recipients with type 1 diabetes;The Lancet Diabetes & Endocrinology;2024-09

2. Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis;Transplantation Reviews;2024-07

3. Late Treatment With Autologous Expanded Regulatory T-cell Therapy After Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation;Transplantation;2024-06-07

4. Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation;Pediatric Transplantation;2024-04-16

5. The Role of Renal Registries;Management of Kidney Diseases;2023